ES2533238T3 - Nanoparticles comprising RNA ligands - Google Patents

Nanoparticles comprising RNA ligands Download PDF

Info

Publication number
ES2533238T3
ES2533238T3 ES05746540.3T ES05746540T ES2533238T3 ES 2533238 T3 ES2533238 T3 ES 2533238T3 ES 05746540 T ES05746540 T ES 05746540T ES 2533238 T3 ES2533238 T3 ES 2533238T3
Authority
ES
Spain
Prior art keywords
nanoparticles
rna ligands
nucleus
ligands
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05746540.3T
Other languages
Spanish (es)
Inventor
Thomas William Rademacher
Khalid Gumaa
Manuel Martin-Lomas
Soledad Penades
Rafael Ojeda
Africa G. Barrientes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midatech Ltd
Original Assignee
Midatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midatech Ltd filed Critical Midatech Ltd
Priority claimed from PCT/GB2005/002058 external-priority patent/WO2005116226A2/en
Application granted granted Critical
Publication of ES2533238T3 publication Critical patent/ES2533238T3/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function

Abstract

Nanopartículas para su uso en un método de terapia, en donde dichas nanopartículas comprenden un núcleo que incluye átomos metálicos y/o semiconductores, y en donde el núcleo está ligado covalentemente a una pluralidad de ligandos que comprende al menos un ligando de ARN que comprende una molécula de ARNip o de miARN.Nanoparticles for use in a therapy method, wherein said nanoparticles comprise a nucleus that includes metal and / or semiconductor atoms, and wherein the nucleus is covalently linked to a plurality of ligands comprising at least one RNA ligand comprising a siRNA or miRNA molecule.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

Claims (1)

imagen1image 1 imagen2image2
ES05746540.3T 2004-05-24 2005-05-24 Nanoparticles comprising RNA ligands Active ES2533238T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57380504P 2004-05-24 2004-05-24
GB0411537 2004-05-24
GBGB0411537.4A GB0411537D0 (en) 2004-05-24 2004-05-24 Nanoparticles comprising rna ligands
US573805P 2004-05-24
PCT/GB2005/002058 WO2005116226A2 (en) 2004-05-24 2005-05-24 Nanoparticles comprising rna ligands

Publications (1)

Publication Number Publication Date
ES2533238T3 true ES2533238T3 (en) 2015-04-08

Family

ID=32607858

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10181903.5T Active ES2655069T3 (en) 2004-05-24 2005-05-24 Nanoparticles comprising RNA ligands
ES05746540.3T Active ES2533238T3 (en) 2004-05-24 2005-05-24 Nanoparticles comprising RNA ligands

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10181903.5T Active ES2655069T3 (en) 2004-05-24 2005-05-24 Nanoparticles comprising RNA ligands

Country Status (3)

Country Link
CN (2) CN102872463B (en)
ES (2) ES2655069T3 (en)
GB (1) GB0411537D0 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
CA2744207C (en) 2008-11-24 2019-05-28 Northwestern University Polyvalent rna-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
KR20120022938A (en) * 2009-04-15 2012-03-12 노오쓰웨스턴 유니버시티 Delivery of oligonucleotide-functionalized nanoparticles
CN102631687A (en) * 2012-05-07 2012-08-15 西安电子科技大学 Multifunctional magnetic nano-carrier for targeted delivery of microRNA, preparation method and application thereof
KR20150020288A (en) * 2012-06-08 2015-02-25 에트리스 게엠베하 Pulmonary delivery of messenger rna
US20150148529A1 (en) * 2012-06-20 2015-05-28 Japan Science And Technology Agency Nucleic acid complex and nucleic acid-polysaccharide complex
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015126502A2 (en) 2013-12-03 2015-08-27 Northwestern University Liposomal particles, methods of making same and uses thereof
CN107106493A (en) 2014-11-21 2017-08-29 西北大学 The sequence-specific cellular uptake of spherical nucleic acid nano particle conjugate
CN111110846B (en) * 2018-10-30 2021-07-23 国家纳米科学中心 Metal-nucleic acid nano-particle and preparation method and application thereof
CN113413467A (en) * 2021-07-01 2021-09-21 清华大学 Carrier-free mRNA delivery method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737598T2 (en) * 1996-07-29 2007-12-27 Nanosphere Inc., Skokie NANOPARTICLES WITH OLIGONUCLEOTIDES ADDITED TO IT AND THEIR USES
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles

Also Published As

Publication number Publication date
CN102872463B (en) 2015-04-08
CN102872463A (en) 2013-01-16
ES2655069T3 (en) 2018-02-16
CN101180400B (en) 2013-07-10
CN101180400A (en) 2008-05-14
GB0411537D0 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
ES2533238T3 (en) Nanoparticles comprising RNA ligands
ES2665917T3 (en) Endoxifene for use in cancer treatment
ES2649340T3 (en) Administration of hypoxia activated drugs and antiangiogenic agents for cancer treatment
ES2609105T3 (en) Covalent linking method of hyaluronic acid and chitosan
ES2502472T3 (en) Adhesive composition for use in an immunosensor
CL2009000040A1 (en) Use of the compound 2,2-dimethyl-n - ((s) -6-oxo-6,7-dihydro-5h-dibenzo [b, d] azepin-7-yl) -n '- (2,2,3 , 3,3-pentafluoro-propyl) -malonamide for the treatment of cancer, in particular of solid tumors, manufacturing methods and kit containing it.
CL2007001624A1 (en) Use of an antibody that binds to dll4 for the treatment of tumor, cancer or cell proliferation disorder.
ES2478820T3 (en) Macular degeneration treatment
ES2534303T3 (en) Procedures and compositions involving miRNA and miRNA inhibitor molecules
BRPI0720546A2 (en) Compound, inhibitor, drug, antitumor agent, pharmaceutical composition, method for treating cancer, and compound use
CR8559A (en) PIRAZOLOPIRIMIDINAS
CL2008001656A1 (en) Anti-c3b antibody; pharmaceutical composition comprising it, and its use to prevent or treat a complement-associated disorder; kit containing it.
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
AR052367A1 (en) METHOD TO CONFORM ABRASIVE ARTICLE WITH STRUCTURE
ECSP088598A (en) DERIVATIVES OF PIRIDAZINONA
BRPI0811816A2 (en) "STABILIZED PICOPLATIN DOSAGE FORM, METHOD FOR PREPARING A STABILIZED PICOPLATIN DOSAGE FORM, COMPOSITIONS, KIT, KIT PLURALITY, METHOD FOR CANCER TREATMENT AND USE OF AN EFFECTIVE AMOUNT OF THE DOSAGE"
ES2531516T3 (en) Use of Escina
GT200300046A (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS AND PROCEDURES FOR USE
PA8636101A1 (en) METHOD FOR THE PREPARATION OF HYDROXAMIC ACIDS
ES2629309T3 (en) Formulations of treatment of mucositis induced by antitumor or immunosuppressive therapy
ATE509933T1 (en) PENTACYCLIC KINASE INHIBITORS
ES2564521T3 (en) Methods and compositions to improve air intake in cement mixtures
CL2009001089A1 (en) Indole-derived compounds [2,1-a] [2] benzacepin; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
ES2586116T3 (en) Procedure and composition for the treatment, prevention and diagnosis of cancer containing cancer stem cells or derivatives thereof
ES2582660T3 (en) Sidnonimines - specific dopamine reuptake inhibitors and their use in the treatment of dopamine-related disorders